Subscribe: pubmed: BMT[Jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0rkpg7psB96kXSn8rHgLXj86RUVpfN48_gOyRQErBE5
Preview: pubmed: BMT[Jour]

pubmed: BMT[Jour]



NCBI: db=pubmed; Term="Bone marrow transplantation"[Jour]



 



Impact of a dedicated post-transplant vaccination service at an Australian cancer centre.
Related Articles

Impact of a dedicated post-transplant vaccination service at an Australian cancer centre.

Bone Marrow Transplant. 2017 Sep 18;:

Authors: Teh BW, Joyce T, Slavin MA, Thursky KA, Worth LJ

PMID: 28920950 [PubMed - as supplied by publisher]




Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.
Related Articles

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.

Bone Marrow Transplant. 2017 Sep 18;:

Authors: Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A

Abstract
Autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) patients with renal insufficiency (RI) is controversial. Patients who underwent AHCT for MM between 2008 and 2013 were identified (N=1492) and grouped as normal/mild (⩾60 mL/min), N=1240, moderate (30-59), N=185 and severe RI (<30), N=67 based on Modification of Diet in Renal Disease. Multivariate analyses of non-relapse mortality (NRM), relapse, PFS and overall survival (OS) were performed. Of the 67 patients with severe RI, 35 were on dialysis prior to AHCT. Patients received melphalan 200 mg/m(2) (Mel 200) in 92% (normal/mild), 75% (moderate) and 33% (severe) RI; remainder received 140 mg/m(2) (Mel 140). Thirty four of 35 patients with severe RI achieved post-AHCT dialysis independence. The 5-year PFS for normal, moderate and severe RI was 35 (95% CI, 31-38)%, 40 (31-49)% and 27 (15-40)%, respectively, (P=0.42); 5-year OS for normal, moderate and severe RI was 68 (65-71)%, 68 (60-76)% and 60 (46-74)%, respectively, (P=0.69). With moderate RI, 5-year PFS for high-dose melphalan 140 mg/m(2) was 18 (6-35)% and for Mel 200 was 46 (36-57)% (P=0.009). With severe RI, 5-year PFS Mel 140 was 25 (11-41) % and for Mel 200 was 32 (11-58)% (P=0.37). We conclude that AHCT is safe and effective in patients with MM with RI.Bone Marrow Transplantation advance online publication, 18 September 2017; doi:10.1038/bmt.2017.198.

PMID: 28920949 [PubMed - as supplied by publisher]




Rejection of paternal vs maternal fully matched bone marrow grafts in children with thalassemia.
Related Articles

Rejection of paternal vs maternal fully matched bone marrow grafts in children with thalassemia.

Bone Marrow Transplant. 2017 Sep 18;:

Authors: Ramprakash S, Agarwal RK, Dhanya R, Sedai A, Kumari A, Parmar L, Srinivas R, Kakulamari VR, Marwah P, Soni R, Williams S, Rathnayake W, Sen S, Tulpule S, Faulkner L

PMID: 28920948 [PubMed - as supplied by publisher]




The capacity-building approach was successful in the start-up process of the first HSCT center in Iraqi Kurdistan.
Related Articles

The capacity-building approach was successful in the start-up process of the first HSCT center in Iraqi Kurdistan.

Bone Marrow Transplant. 2017 Sep 18;:

Authors: Majolino I, Rovelli A, Vacca M, Verna M, Canesi M, Conter V, Othman D

PMID: 28920947 [PubMed - as supplied by publisher]




Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation.
Related Articles

Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation.

Bone Marrow Transplant. 2017 Sep 18;:

Authors: Zeng Y, Katsanis E

PMID: 28920946 [PubMed - as supplied by publisher]